Log in

Relevant bibliographies by topics / Booster Vaccines / Journal articles

To see the other types of publications on this topic, follow the link: Booster Vaccines.

Journal articles on the topic 'Booster Vaccines'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Booster Vaccines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Turabian, Jose Luis. "Relative and Temporal Efficacy of the First and Second Covid 19 Booster Vaccine (3rd And 4th Dose) to Prevent Symptomatic Infection from December 2021 to October 2023 in a General Medicine Office in Toledo (Spain)." Journal of Health Care and Research 5, no. 1 (2024): 39–48. http://dx.doi.org/10.36502/2024/hcr.6234.

Full text

Abstract:

Background: The effectiveness of COVID-19 vaccines in preventing serious infection and death is established, but their protection against infection is less certain. Additionally, their effectiveness diminishes over time. Furthermore, the evolution of the effectiveness of different booster doses of the vaccine against COVID-19, to prevent symptomatic infection in real life during the pandemic and the subsequent endemic, is not clearly documented. Objective: To compare the effectiveness of the 3rd and 4th vaccine boosters against COVID-19 in preventing symptomatic COVID-19 infection during both

APA, Harvard, Vancouver, ISO, and other styles

2

Handayani, Ety Sari, and Nurul Hidayah. "Heterologous Booster Profiles for Recipeints of CoronaVac Inactivated Primary Vaccine: A Scoping Review." Indonesian Journal of Clinical Pharmacy 12, no. 1 (2024): 68–85. https://doi.org/10.15416/ijcp.2023.12.1.68.

Full text

Abstract:

The administration of booster vaccines has been implemented in a number of countries. Unfortunately, there are limited studies of the immune response after booster to recipient with CoronaVac inactivated primary vaccine. This scoping review aims to determine heterologous booster profiles for recipients of the CoronaVac inactivated primary vaccine. This study obtained data from PubMed, Cochrane Library, Medrxiv, Google Scholar and Grey literature. The inclusion criteria were Sars-Cov-2 article, heterologous boosters and CoronaVac vaccine published from 2020 to 2022, written in English, and in a

APA, Harvard, Vancouver, ISO, and other styles

3

Motta, Matt. "The Correlates & Public Health Consequences of Prospective Vaccine Hesitancy among Individuals Who Received COVID-19 Vaccine Boosters in the U.S." Vaccines 10, no. 11 (2022): 1791. http://dx.doi.org/10.3390/vaccines10111791.

Full text

Abstract:

Supplemental “booster” vaccines may prove vital in combating variant waves of endemic COVID-19. Given relatively low levels of booster vaccine uptake, Americans’ willingness to receive a second booster shot is unclear. In a demographically representative survey of N = 3950 US adults (limited to a “boosted” subsample of N = 1551 who had not yet received a second booster), 49% [95% CI: 47, 51] of Americans report having received an initial booster shot, while just 34% [33, 36] report that they would be “very likely” to do so again. Concerns about missing work to vaccinate (−10%; B = 0.53, p = 0.

APA, Harvard, Vancouver, ISO, and other styles

4

ROMBAOA, MARNIE GERALDINE. "Pediatric COVID-19 Booster Hesitancy Among Mothers: Basis for A Proposed Health Education Program." WORLD EDUCATION CONNECT Multidisciplinary e-Publication IV, no. I (2024): 16. https://doi.org/10.5281/zenodo.10559770.

Full text

Abstract:

As the COVID-19 pandemic continues, and transitions to an endemic stage, booster vaccines play an important role in personal, and public health. Convincing people to take boosters continues to be a key problem.  Despite the availability of clinically tested, and effective COVID-19 booster vaccines, convincing people to accept boosters remains a significant challenge. As of 18 January 2023, only 15.3% of the total population in the United States (U.S.) had received the bivalent COVID-19 booster vaccine. In addition, previous research showed people in many countries, especially in low-incom

APA, Harvard, Vancouver, ISO, and other styles

5

Hurst, Jacklyn R., Maedeh Naghibosadat, Patrick Budowski, et al. "Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice." PLOS ONE 19, no. 12 (2024): e0314061. https://doi.org/10.1371/journal.pone.0314061.

Full text

Abstract:

The emergence of SARS-CoV-2 variants presents challenges to vaccine effectiveness, underlining the necessity for next-generation vaccines with multiple antigens beyond the spike protein. Here, we investigated a multiantigenic booster containing spike and a chimeric construct composed of nucleoprotein (N) and membrane (M) proteins, comparing its efficacy to a spike-only booster against Omicron BA.5 in K18-hACE2 mice. Initially, mice were primed and boosted with Beta (B.1.351) spike-only mRNA, showing strong spike-specific T cell responses and neutralizing antibodies, albeit with limited cross-n

APA, Harvard, Vancouver, ISO, and other styles

6

Kamal, Sanaa M., Moheyeldeen Mohamed Naghib, Moataz Daadour, et al. "The Outcome of BNT162b2, ChAdOx1-Sand mRNA-1273 Vaccines and Two Boosters: A Prospective Longitudinal Real-World Study." Viruses 15, no. 2 (2023): 326. http://dx.doi.org/10.3390/v15020326.

Full text

Abstract:

To date, the effectiveness of COVID-19 vaccines and booster doses has yet to be evaluated in longitudinal head-to-head studies. This single-center longitudinal study assessed the effectiveness of ChAdOx1 nCoV-19, BNT162b2, and mRNA-1273 vaccines and assessed two BNT162b2 boosters in 1550 participants, of whom 26% had comorbidities. In addition, the SARS-CoV-2 antibody dynamics was monitored. A group of 1500 unvaccinated subjects was included as the controls. The study’s endpoint was the development of virologically-proven COVID-19 cases after vaccine completion, while the secondary endpoint wa

APA, Harvard, Vancouver, ISO, and other styles

7

Sirison, Kanchanok, Natthaprang Nittayasoot, Ranida Techasuwanna, Nisachol Cetthakrikul, and Rapeepong Suphanchaimat. "Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance." Tropical Medicine and Infectious Disease 8, no. 2 (2023): 91. http://dx.doi.org/10.3390/tropicalmed8020091.

Full text

Abstract:

The Thai government implemented COVID-19 booster vaccines to prevent morbidity and mortality during the spreading of the Omicron variant. However, little is known about which types of vaccine should be invested in as the booster dose for the Thai population. This study aims to investigate the most cost-effective COVID-19 vaccine for a booster shot as empirical evidence for Thai policymakers. This study applied a stochastic simulation based on a compartmental susceptible-exposed-infectious-recovered model and included system dynamics in the model. We evaluated three scenarios: (1) No booster, (

APA, Harvard, Vancouver, ISO, and other styles

8

Lounis, Mohamed, Djihad Bencherit, Mohammed Amir Rais, and Abanoub Riad. "COVID-19 Vaccine Booster Hesitancy (VBH) and Its Drivers in Algeria: National Cross-Sectional Survey-Based Study." Vaccines 10, no. 4 (2022): 621. http://dx.doi.org/10.3390/vaccines10040621.

Full text

Abstract:

Due to the emergence of various highly contagious variants of SARS-CoV-2, vaccine boosters were adopted as a complementary strategy in different countries. This strategy has, however, posed another challenge for the national authorities to convince their population to receive the booster after the first challenge of COVID-19 primer dose vaccines. This study was conducted to determine COVID-19 vaccine booster acceptance and its associated factors in the general population in Algeria. Using social media platforms, an online self-administered questionnaire was distributed between 28 January and 5

APA, Harvard, Vancouver, ISO, and other styles

9

Lin, Zhi-Qiang, Jiang-Nan Wu, Rong-Dong Huang, et al. "Comparison of Safety of Different Vaccine Boosters Following Two-Dose Inactivated Vaccines: A Parallel Controlled Prospective Study." Vaccines 10, no. 4 (2022): 622. http://dx.doi.org/10.3390/vaccines10040622.

Full text

Abstract:

A vaccine booster to maintain high antibody levels and provide effective protection against COVID-19 has been recommended. However, little is known about the safety of a booster for different vaccines. We conducted a parallel controlled prospective study to compare the safety of a booster usingfour common vaccines in China. In total, 320 eligible participants who had received two doses of an inactivated vaccine were equally allocated to receive a booster of the same vaccine (Group A), a different inactivated vaccine (Group B), an adenovirus type-5 vectored vaccine (Group C), or a protein subun

APA, Harvard, Vancouver, ISO, and other styles

10

Limbu, Yam B., and Bruce A. Huhmann. "Why Some People Are Hesitant to Receive COVID-19 Boosters: A Systematic Review." Tropical Medicine and Infectious Disease 8, no. 3 (2023): 159. http://dx.doi.org/10.3390/tropicalmed8030159.

Full text

Abstract:

As the COVID-19 pandemic continues and transitions to an endemic stage, booster vaccines will play an important role in personal and public health. However, convincing people to take boosters continues to be a key obstacle. This study systematically analyzed research that examined the predictors of COVID-19 booster vaccine hesitancy. A search of PubMed, Medline, CINAHL, Web of Science, and Scopus uncovered 42 eligible studies. Globally, the average COVID-19 booster vaccination hesitancy rate was 30.72%. Thirteen key factors influencing booster hesitancy emerged from the literature: demographic

APA, Harvard, Vancouver, ISO, and other styles

11

Luxi, Nicoletta, Francesco Ciccimarra, Chiara Bellitto, et al. "Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study." Vaccines 12, no. 9 (2024): 1059. http://dx.doi.org/10.3390/vaccines12091059.

Full text

Abstract:

Background: Conventional vaccines rarely cause severe allergic reactions. However, the rapid development and approval of COVID-19 vaccines left limited initial data on their adverse reactions, particularly in individuals with a history of allergy. The aim of this study was to assess and compare the safety profile of different doses and brands of COVID-19 vaccines in subjects with a history of allergy vs. those without a history of allergy. Methods: From February 2021 to February 2023, a web-based prospective study gathered vaccinee-reported outcomes using electronic questionnaires across eleve

APA, Harvard, Vancouver, ISO, and other styles

12

Faraz, Ali, Malik Hina, Ali Atif, et al. "Knowledge, acceptance, motivators and barriers of booster dose of COVID-19 vaccination among dental patients: A cross-sectional study." Medicine 102, no. 45 (2023): e35747. http://dx.doi.org/10.1097/md.0000000000035747.

Full text

Abstract:

Given the lingering threat of COVID infection, questions are being raised if coronavirus disease 2019 (COVID-19) vaccine needs annual or regular boosters to maintain high levels of immunity against both the original virus and variants. This study was designed to evaluate the knowledge, acceptance, motivators and barriers of the booster dose of COVID-19 vaccine among the dental patients of District Lucknow, India. A total of 297 respondents were selected by a convenience sampling method in this cross-sectional study from various dental clinics. An anonymous, self-administered, closed-ended ques

APA, Harvard, Vancouver, ISO, and other styles

13

Suluh Gembyeng Ciptadi and Alfath Marzuki. "SOCIAL MEDIA ANALYTICS OF BOOSTER VACCINE COVID-19 DISCOURSE ON TWITTER." Sunan Ampel Review of Political and Social Sciences 2, no. 2 (2023): 118–28. http://dx.doi.org/10.15642/sarpass.2023.2.2.118-128.

Full text

Abstract:

People around the world are currently carrying out booster vaccinations in the midst of the outbreak of the Omicron variant of the COVID-19 virus. In Indonesia, vaccine booster activities have been carried out since January 12, 2022. The Indonesian government makes vaccines free and encourages the public to immediately carry out vaccine booster. Vaccine booster information and campaigns also appear on social media. Twitter as one of the social media that is widely used in Indonesia is also enlivened with discussions about vaccine boosters. The objective of this research is to see how the vacci

APA, Harvard, Vancouver, ISO, and other styles

14

Yadete, Tesfaye, Kavita Batra, Dale M. Netski, Sabrina Antonio, Michael J. Patros, and Johan C. Bester. "Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study." Vaccines 9, no. 12 (2021): 1424. http://dx.doi.org/10.3390/vaccines9121424.

Full text

Abstract:

Given the emergence of breakthrough infections, new variants, and concerns of waning immunity from the primary COVID-19 vaccines, booster shots emerged as a viable option to shore-up protection against COVID-19. Following the recent authorization of vaccine boosters among vulnerable Americans, this study aims to assess COVID-19 vaccine booster hesitancy and its associated factors in a nationally representative sample. A web-based 48-item psychometric valid survey was used to measure vaccine literacy, vaccine confidence, trust, and general attitudes towards vaccines. Data were analyzed through

APA, Harvard, Vancouver, ISO, and other styles

15

Luan, Ning, Han Cao, Yunfei Wang, Kangyang Lin, Jingping Hu, and Cunbao Liu. "Comparison of Immune Responses between Inactivated and mRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice." Viruses 15, no. 6 (2023): 1351. http://dx.doi.org/10.3390/v15061351.

Full text

Abstract:

A large amount of real-world data suggests that the emergence of variants of concern (VOCs) has brought new challenges to the fight against SARS-CoV-2 because the immune protection elicited by the existing coronavirus disease 2019 (COVID-19) vaccines was weakened. In response to the VOCs, it is necessary to advocate for the administration of booster vaccine doses to extend the effectiveness of vaccines and enhance neutralization titers. In this study, the immune effects of mRNA vaccines based on the WT (prototypic strain) and omicron (B1.1.529) strains for use as booster vaccines were investig

APA, Harvard, Vancouver, ISO, and other styles

16

Léger, Camille, Frédérique Deslauriers, Vincent Gosselin Boucher, Meghane Phillips, Simon L. Bacon, and Kim L. Lavoie. "Prevalence and Motivators of Getting a COVID-19 Booster Vaccine in Canada: Results from the iCARE Study." Vaccines 11, no. 2 (2023): 291. http://dx.doi.org/10.3390/vaccines11020291.

Full text

Abstract:

Studies have shown that the protection afforded by COVID-19 vaccines against hospitalization and death decreases slowly over time due to the emergence of new variants and waning immunity. Accordingly, booster doses remain critical to minimizing the health impacts of the pandemic. This study examined the prevalence rate, sociodemographic determinants, and motivators of getting a COVID-19 booster vaccine within the Canadian population. We recruited a representative sample of 3001 Canadians aged 18+ years as part of the iCARE study using an online polling form between 20 January and 2 February 20

APA, Harvard, Vancouver, ISO, and other styles

17

Muñoz-Gómez, María José, Pablo Ryan, Marta Quero-Delgado, et al. "Antibody Response Against SARS-CoV-2 Spike Protein in People with HIV After COVID-19 Vaccination." Vaccines 13, no. 5 (2025): 480. https://doi.org/10.3390/vaccines13050480.

Full text

Abstract:

Background/Objectives: People with HIV (PWH) often have a suboptimal response to vaccines, raising concerns regarding the efficacy of coronavirus disease 2019 (COVID-19) vaccines in this population. We aimed to evaluate the humoral immune response to the B.1 lineage and Omicron variant in PWH on antiretroviral therapy (ART) following COVID-19 vaccination. Methods: We conducted a prospective study of 19 PWH on ART who received a two-dose series of the COVID-19 mRNA vaccine and a booster six months later. Participants without HIV infection (n = 25) were included as a healthy control (HC) group.

APA, Harvard, Vancouver, ISO, and other styles

18

Pérez-Then, Eddy, Carolina Lucas, Valter Silva Monteiro, et al. "Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination." Nature Medicine 28, no. 3 (2022): 481–85. http://dx.doi.org/10.1038/s41591-022-01705-6.

Full text

Abstract:

AbstractThe recent emergence of the SARS-CoV-2 Omicron variant is raising concerns because of its increased transmissibility and its numerous spike mutations, which have the potential to evade neutralizing antibodies elicited by COVID-19 vaccines. Here we evaluated the effects of a heterologous BNT162b2 mRNA vaccine booster on the humoral immunity of participants who had received a two-dose regimen of CoronaVac, an inactivated vaccine used globally. We found that a heterologous CoronaVac prime vaccination of two doses followed by a BNT162b2 booster induces elevated virus-specific antibody leve

APA, Harvard, Vancouver, ISO, and other styles

19

Vu Huy Thong, Dung Phuong Hoang, Vu Hong Hanh, Van Hoang, Vu Mai Huong, and Dinh Dieu Ha. "Accelerating the adoption of booster vaccine shots: From the psychological and behavioural perspectives." Journal of Namibian Studies : History Politics Culture 34 (June 2, 2023): 2180–204. http://dx.doi.org/10.59670/jns.v34i.1496.

Full text

Abstract:

Taking booster vaccines plays a critical role to enhance the effectiveness of vaccine programs and their positive externalities to community health. This study treats the booster vaccine as a value and expands the theory of planned behaviour to examine determinants of behaviours to take that value among the public. Mixed research methods are used in this study. While qualitative data from the in-depth interviews support the identification of new themes serving the development of hypotheses and measurement scales, quantitative data from 771 respondents from all walks of life are employed to pro

APA, Harvard, Vancouver, ISO, and other styles

20

Al Janabi, Taysir, and Maria Pino. "Predictors for Actual COVID-19 Vaccine Uptake and Intended Booster Dosage among Medical Students of an Osteopathic Medical School in New York." Epidemiologia 2, no. 4 (2021): 553–63. http://dx.doi.org/10.3390/epidemiologia2040038.

Full text

Abstract:

Exploring future physicians’ attitudes toward vaccination is crucial as physicians’ recommendation is the top predictor for individuals to receive vaccines. This study explored the uptake of COVID-19 vaccines and the intention for future booster dose uptake among students at the New York Institute of Technology College of Osteopathic Medicine (NYITCOM). Predictors for actual vaccine and intended booster uptake were also examined. An electronic survey was distributed to Osteopathic Medical Students (OMS I-IV) in the Spring of 2021. A total of 1331 students received the survey, with 316 response

APA, Harvard, Vancouver, ISO, and other styles

21

Atanasov, Vladimir, Natalia Barreto, Jeff Whittle, et al. "Understanding COVID-19 Vaccine Effectiveness against Death Using a Novel Measure: COVID Excess Mortality Percentage." Vaccines 11, no. 2 (2023): 379. http://dx.doi.org/10.3390/vaccines11020379.

Full text

Abstract:

COVID-19 vaccines have saved millions of lives; however, understanding the long-term effectiveness of these vaccines is imperative to developing recommendations for booster doses and other precautions. Comparisons of mortality rates between more and less vaccinated groups may be misleading due to selection bias, as these groups may differ in underlying health status. We studied all adult deaths during the period of 1 April 2021–30 June 2022 in Milwaukee County, Wisconsin, linked to vaccination records, and we used mortality from other natural causes to proxy for underlying health. We report re

APA, Harvard, Vancouver, ISO, and other styles

22

Flores-Lastra, Nancy, Josue Rivadeneira-Dueñas, Luis Fuenmayor-González, et al. "Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study." Vaccines 11, no. 3 (2023): 676. http://dx.doi.org/10.3390/vaccines11030676.

Full text

Abstract:

More than 600 healthcare workers died due to COVID-19 infection until January 2022 in Ecuador. Even though the COVID-19 vaccines are safe, local and systemic reactions were reported among physicians. This study aims to analyze the adverse events of COVID-19 with an emphasis on comparing the homologous and heterologous booster doses in physicians that received three approved vaccines in Ecuador. An electronic survey was performed in Quito, Ecuador, directed at physicians who were vaccinated with the three doses of COVID-19 vaccines. A total of 210 participants were analyzed after administering

APA, Harvard, Vancouver, ISO, and other styles

23

Young-Xu, Yinong, Gabrielle M. Zwain, Hector S. Izurieta, et al. "Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case–control study among US veterans." BMJ Open 12, no. 8 (2022): e063935. http://dx.doi.org/10.1136/bmjopen-2022-063935.

Full text

Abstract:

ObjectiveTo estimate the effectiveness of messenger RNA (mRNA) booster doses during the period of Delta and Omicron variant dominance.DesignWe conducted a matched test-negative case–control study to estimate the vaccine effectiveness (VE) of three and two doses of mRNA vaccines against infection (regardless of symptoms) and against COVID-19-related hospitalisation and death.SettingVeterans Health Administration.ParticipantsWe used electronic health record data from 114 640 veterans who had a SARS-CoV-2 test during November 2021–January 2022. Patients were largely 65 years or older (52%), male

APA, Harvard, Vancouver, ISO, and other styles

24

Matsui, Tamires Cardoso, Amanda Campelo Lima De Melo, Maria da Conceição Rodrigues Fernandes, Germana Silva Vasconcelos, Marcela Helena Gambim Fonseca, and Fernanda Montenegro de Carvalho Araujo. "Antibody response to different COVID-19 vaccine regimes: a review." Brazilian Journal of Health Review 7, no. 1 (2024): 488–506. http://dx.doi.org/10.34119/bjhrv7n1-036.

Full text

Abstract:

COVID-19 pandemic initiated a race for the development of vaccines. Different technologies have been used to produce them, including inactivated whole-virus, nucleic acid, and adenovirus vector platforms. COVID-19 vaccination was initiated with two doses called “primary vaccination” which can be homologous (the same vaccine used in the first and second dose) or heterologous (different vaccines used in the first and second dose). Waning of vaccine-induced antibodies over time combined with the emerging SARS-CoV-2 variants of concern (VOCs) suggested the importance and necessity of a “booster sh

APA, Harvard, Vancouver, ISO, and other styles

25

Wong, Matthew Tze Jian, Satvinder Singh Dhaliwal, Venugopal Balakrishnan, Fazlina Nordin, Mohd Nor Norazmi, and Gee Jun Tye. "Effectiveness of Booster Vaccinations on the Control of COVID-19 during the Spread of Omicron Variant in Malaysia." International Journal of Environmental Research and Public Health 20, no. 2 (2023): 1647. http://dx.doi.org/10.3390/ijerph20021647.

Full text

Abstract:

(1) Background: The assessment of vaccine effectiveness against the Omicron variant is vital in the fight against COVID-19, but research on booster vaccine efficacy using nationwide data was lacking at the time of writing. This study investigates the effectiveness of booster doses on the Omicron wave in Malaysia against COVID-19 infections and deaths; (2) Methods: This study uses nationally representative data on COVID-19 from 1 January to 31 March 2022, when the Omicron variant was predominant in Malaysia. Daily new infections, deaths, ICU utilization and Rt values were compared. A screening

APA, Harvard, Vancouver, ISO, and other styles

26

Wei, Yunhua, Yan Wang, Jian Liu, et al. "Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous orHeterologous COVID-19 Booster Vaccinations." Vaccines 10, no. 11 (2022): 1869. http://dx.doi.org/10.3390/vaccines10111869.

Full text

Abstract:

Objective: A comparative analysis was performed to investigate the potential risk factors of Adverse Events Following Immunization (AEFI) after receiving different booster vaccines. Methods: From 18 January 2021 to 21 January 2022, the Health Care Workers (HCWs) of Guizhou Provincial Staff Hospital (Guizhou Province, China) who received a third Booster vaccine, that was either homologous (i.e., (i) a total of three doses of Vero cell vaccine or (ii) three doses of CHO cell vaccine) or (iii) heterologous with two first doses of Vero cell vaccine, being either CHO cell vaccine or adenovirus type

APA, Harvard, Vancouver, ISO, and other styles

27

Chia, Travis Ren Teen, Barnaby Edward Young, and Po Ying Chia. "The Omicron-transformer: Rise of the subvariants in the age of vaccines." Annals of the Academy of Medicine, Singapore 51, no. 11 (2022): 712–29. http://dx.doi.org/10.47102/annals-acadmedsg.2022294.

Full text

Abstract:

Introduction: Omicron is the latest SARS-CoV-2 variant of concern, the pathogen that causes COVID-19. Since its emergence in late 2021, Omicron has displaced other circulating variants and caused successive waves of infection worldwide throughout 2022. Omicron is characterised by the rapid emergence of many subvariants and high rates of infection in people with vaccine- and/or infection-induced immunity. This review article will consolidate current knowledge regarding Omicron subvariants, the role of boosters, and future vaccine development. Method: This narrative review is based on a literatu

APA, Harvard, Vancouver, ISO, and other styles

28

Dangi, Tanushree, Sarah Sanchez, Min Han Lew, et al. "Pre-existing immunity modulates responses to mRNA boosters." Journal of Immunology 210, no. 1_Supplement (2023): 59.05. http://dx.doi.org/10.4049/jimmunol.210.supp.59.05.

Full text

Abstract:

Abstract mRNA vaccines have shown high efficacy in preventing severe COVID-19, but breakthrough infections, emerging variants and waning antibody levels have warranted the use of boosters. Although mRNA boosters have been widely implemented, the extent to which pre-existing immunity influences the efficacy of boosters remains unclear. In a cohort of individuals primed with the mRNA-1273 or BNT162b2 vaccines, we observed that lower spike-specific antibody levels before boost were associated with higher fold-increase in spike-specific antibody levels after boost, suggesting that pre-existing ant

APA, Harvard, Vancouver, ISO, and other styles

29

Dangi, Tanushree, Nicole Palacio, Sarah Sanchez, et al. "Cross-protection by SARS vaccines is improved by booster vaccination." Journal of Immunology 208, no. 1_Supplement (2022): 125.21. http://dx.doi.org/10.4049/jimmunol.208.supp.125.21.

Full text

Abstract:

Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines have shown extraordinary efficacy against SARS-CoV-2. Recently, we demonstrated that prime-boost coronavirus vaccine regimens can protect against heterologous coronaviruses (Dangi, The Journal of Clinical Investigation, 2021). However, it remains unclear whether boosters are required for such cross-protection. In this study, we show that booster immunizations are critical to elicit cross-protection against heterologous coronaviruses. We first vaccinated BALB/c mice intramuscularly with a poxvirus-based SARS-CoV-1 va

APA, Harvard, Vancouver, ISO, and other styles

30

Hossain, Ismail, Jannatul Ferdous Subarna, Congriev Kumar Kabiraj, et al. "A Booster with a Genotype-Matched Inactivated Newcastle Disease Virus (NDV) Vaccine Candidate Provides Better Protection against a Virulent Genotype XIII.2 Virus." Vaccines 11, no. 5 (2023): 1005. http://dx.doi.org/10.3390/vaccines11051005.

Full text

Abstract:

Newcastle disease (ND) is endemic in Bangladesh. Locally produced or imported live Newcastle disease virus (NDV) vaccines based on lentogenic virus strains, locally produced live vaccines of the mesogenic Mukteswar strain, as well as imported inactivated vaccines of lentogenic strains, are being used in Bangladesh under different vaccination regimens. Despite these vaccinations, frequent outbreaks of ND are being reported in Bangladesh. Here we compared the efficacy of booster immunization with three different vaccines in chickens that had been primed with two doses of live LaSota vaccine. A t

APA, Harvard, Vancouver, ISO, and other styles

31

Bouros, Ioana, Edward M. Hill, Matt J. Keeling, Sam Moore, and Robin N. Thompson. "Prioritising older individuals for COVID-19 booster vaccination leads to optimal public health outcomes in a range of socio-economic settings." PLOS Computational Biology 20, no. 8 (2024): e1012309. http://dx.doi.org/10.1371/journal.pcbi.1012309.

Full text

Abstract:

The rapid development of vaccines against SARS-CoV-2 altered the course of the COVID-19 pandemic. In most countries, vaccinations were initially targeted at high-risk populations, including older individuals and healthcare workers. Now, despite substantial infection- and vaccine-induced immunity in host populations worldwide, waning immunity and the emergence of novel variants continue to cause significant waves of infection and disease. Policy makers must determine how to deploy booster vaccinations, particularly when constraints in vaccine supply, delivery and cost mean that booster vaccines

APA, Harvard, Vancouver, ISO, and other styles

32

Abdullah, Noor Shahira, Siew Mooi Ching, and Hanifatiyah Ali. "Willingness to receive a COVID-19 booster vaccine and its associated factors among adults with chronic disease: A cross-sectional study in Putrajaya, Malaysia." Malaysian Family Physician 18 (May 23, 2023): 30. http://dx.doi.org/10.51866/oa.260.

Full text

Abstract:

Introduction: Booster vaccination has been shown to reduce transmission and serious infection with COVID-19. This study examined the willingness to receive a COVID-19 booster vaccine and its associated factors among high-risk patients at Klinik Kesihatan Putrajaya Presint 9. Methods: A cross-sectional study was conducted among patients aged ≥18 years attending Klinik Kesihatan Putrajaya Presint 9 with a high risk of contracting COVID-19 recruited via systematic random sampling. Data were collected using a self-administered questionnaire. A multiple logistic regression analysis was performed to

APA, Harvard, Vancouver, ISO, and other styles

33

Kanokudom, Sitthichai, Suvichada Assawakosri, Nungruthai Suntronwong, et al. "Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine." Vaccines 10, no. 1 (2022): 86. http://dx.doi.org/10.3390/vaccines10010086.

Full text

Abstract:

The coronavirus disease 2019 (COVID-19) pandemic has become a severe healthcare problem worldwide since the first outbreak in late December 2019. Currently, the COVID-19 vaccine has been used in many countries, but it is still unable to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, despite patients receiving full vaccination doses. Therefore, we aimed to appraise the booster effect of the different platforms of vaccines, including inactivated vaccine (BBIBP), viral vector vaccine (AZD122), and mRNA vaccine (BNT162b2), in healthy adults who receiv

APA, Harvard, Vancouver, ISO, and other styles

34

Shekhar, Rahul, Ishan Garg, Suman Pal, Saket Kottewar, and Abu Baker Sheikh. "COVID-19 Vaccine Booster: To Boost or Not to Boost." Infectious Disease Reports 13, no. 4 (2021): 924–29. http://dx.doi.org/10.3390/idr13040084.

Full text

Abstract:

Developing safe and effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at a breakneck speed has been an exceptional human achievement. It remains our best hope of containing the coronavirus disease 2019 (COVID-19) pandemic. However, newer, more aggressive SARS-CoV-2 viral strains, as well as the possibility of fading immunity following vaccination, have prompted health officials to investigate the necessity for additional immunization. This has put further pressure on disregarded human life in lower-income countries that already have minimal access to COVID

APA, Harvard, Vancouver, ISO, and other styles

35

Zhang, Zhiren, Qiaren He, Wei Zhao, et al. "A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains." Journal of Clinical Medicine 11, no. 14 (2022): 4164. http://dx.doi.org/10.3390/jcm11144164.

Full text

Abstract:

Immune escape of emerging SARS-CoV-2 variants of concern (VOCs) and waning immunity over time following the primary series suggest the importance and necessity of booster shot of COVID-19 vaccines. With the aim to preliminarily evaluate the potential of heterologous boosting, we conducted two pilot studies to evaluate the safety and immunogenicity of the V-01 or a bivalent V-01D-351 (targeting Delta and Beta strain) booster after 5–7 months of the primary series of inactivated COVID-9 vaccine (ICV). A total of 77 participants were enrolled, with 20 participants in the V-01D-351 booster study,

APA, Harvard, Vancouver, ISO, and other styles

36

Intawong, Kannikar, Suwat Chariyalertsak, Kittipan Chalom, et al. "Waning vaccine response to severe COVID-19 outcomes during omicron predominance in Thailand." PLOS ONE 18, no. 5 (2023): e0284130. http://dx.doi.org/10.1371/journal.pone.0284130.

Full text

Abstract:

Background The COVID-19 pandemic has evolved quickly, with different variants of concern resulting in the need to offer continued protection through booster vaccinations. The duration of enhanced protection with booster doses against severe COVID-19 is still unclear. Understanding this is critical to recommendations on the frequency of future booster doses. Methods Utilising a Hospital Information System for COVID-19 established in Chiang Mai, Thailand, we conducted a cohort study by linking patient-level data of laboratory-confirmed COVID-19 cases to the national immunization records, during

APA, Harvard, Vancouver, ISO, and other styles

37

Yuan, Lin, Madison Stoddard, Sharanya Sarkar, et al. "The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis." Vaccines 13, no. 4 (2025): 368. https://doi.org/10.3390/vaccines13040368.

Full text

Abstract:

Background: While the rapid deployment of SARS-CoV-2 vaccines had a significant impact on the ongoing COVID-19 pandemic, rapid viral immune evasion and waning neutralizing antibody titers have degraded vaccine efficacy. Nevertheless, vaccine manufacturers and public health authorities have a number of options at their disposal to maximize the benefits of vaccination. In particular, the effect of booster schedules on vaccine performance bears further study. Methods: To better understand the effect of booster schedules on vaccine performance, we used an agent-based modeling framework and a popul

APA, Harvard, Vancouver, ISO, and other styles

38

Pratama, Gita, Mila Maidarti, Kanadi Sumapradja, et al. "Knowledge, attitudes, and practices regarding Covid-19 and their relationship with Covid-19 booster vaccination status among women with infertility." Asian Pacific Journal of Reproduction 13, no. 2 (2024): 68–75. http://dx.doi.org/10.4103/apjr.apjr_113_23.

Full text

Abstract:

Objective: To elucidate the relationship among knowledge, attitudes, and practices regarding Covid-19 and their relationship with booster vaccination status among women with infertility. Methods: This questionnaire-based cross-sectional study was performed online and offline among women with infertility who visited an infertility clinic in Jakarta, Indonesia. We assessed the patient’s knowledge, attitudes, and practices regarding Covid- 19 and their relationship with booster vaccination status and sociodemographic profile. Results: A total of 178 subjects participated in this study, and most p

APA, Harvard, Vancouver, ISO, and other styles

39

Ciccimarra, Francesco, Nicoletta Luxi, Chiara Bellitto, et al. "Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study." Vaccines 12, no. 3 (2024): 241. http://dx.doi.org/10.3390/vaccines12030241.

Full text

Abstract:

In all pivotal trials of COVID-19 vaccines, the history of previous SARS-CoV-2 infection was mentioned as one of the main exclusion criteria. In the absence of clinical trials, observational studies are the primary source for evidence generation. This study aims to describe the patient-reported adverse drug reactions (ADRs) following the first COVID-19 vaccination cycle, as well as the administration of booster doses of different vaccine brands, in people with prior SARS-CoV-2 infection, as compared to prior infection-free matched cohorts of vaccinees. A web-based prospective study was conduct

APA, Harvard, Vancouver, ISO, and other styles

40

Maiella, Richard A., Kelly M. Staples, and Ashokvardhan Veldanda. "Migratory dermatographic urticaria following COVID-19 vaccine booster in young adult male." AIMS Allergy and Immunology 6, no. 1 (2022): 14–18. http://dx.doi.org/10.3934/allergy.2022003.

Full text

Abstract:

<abstract> <p>With the recent approval of booster vaccinations in the United States for adults who already received their primary vaccinations, millions of adults have been administered the Pfizer-BioNTech or Moderna booster vaccines. Adverse events related to these vaccines continue to be reported and are majority self-limited. In this case report, we present a young male who acquired chronic, migratory dermatographic urticaria two weeks after administration of the Moderna mRNA-1273 COVID-19 vaccine booster.</p> </abstract>

APA, Harvard, Vancouver, ISO, and other styles

41

Sophonmanee, Ratchanon, Perawas Preampruchcha, Jomkwan Ongarj, et al. "Intradermal Fractional ChAdOx1 nCoV-19 Booster Vaccine Induces Memory T Cells: A Follow-Up Study." Vaccines 12, no. 2 (2024): 109. http://dx.doi.org/10.3390/vaccines12020109.

Full text

Abstract:

The administration of viral vector and mRNA vaccine booster effectively induces humoral and cellular immune responses. Effector T cell responses after fractional intradermal (ID) vaccination are comparable to those after intramuscular (IM) boosters. Here, we quantified T cell responses after booster vaccination. ChAdOx1 nCoV-19 vaccination induced higher numbers of S1-specific CD8+ memory T cells, consistent with the antibody responses. Effector memory T cell phenotypes elicited by mRNA vaccination showed a similar trend to those elicited by the viral vector vaccine booster. Three months post-

APA, Harvard, Vancouver, ISO, and other styles

42

Aguilera, Ximena, Juan Hormazábal, Cecilia Vial, et al. "SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes." Vaccines 10, no. 7 (2022): 1051. http://dx.doi.org/10.3390/vaccines10071051.

Full text

Abstract:

Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.

APA, Harvard, Vancouver, ISO, and other styles

43

Makri, Eleni, Ekatherina Charvalos, Elisavet Stavropoulou, Constantina Skanavis, Areti Lagiou, and Anastasia Barbounis. "Immunological Insights: A Multicenter Longitudinal Study on Humoral Response to COVID-19 Vaccines in Greece." Acta Microbiologica Hellenica 69, no. 2 (2024): 101–13. http://dx.doi.org/10.3390/amh69020011.

Full text

Abstract:

Vaccination has emerged as the most effective tool in the battle against COVID-19. To optimize vaccination protocols, a deeper understanding of the immune response to vaccination, including influential factors and its duration, is essential. This study aimed to assess the humoral response in vaccinated individuals with or without prior SARS-CoV-2 infection. A prospective observational study was conducted across 14 private healthcare structures in Greece. Anti-spike IgG titers were measured at different timepoints following the initial vaccination and booster doses of the BNT162b2, mRNA-1273, C

APA, Harvard, Vancouver, ISO, and other styles

44

Chen, Po-Yu, Bih-Ju Wu, Mei-Chin Su, et al. "Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose." Vaccines 10, no. 7 (2022): 1115. http://dx.doi.org/10.3390/vaccines10071115.

Full text

Abstract:

With the spread of the new SARS-CoV-2 variants, many countries have begun COVID-19 vaccine booster programs with the mix-and-match strategy. However, research on the adverse events (AE) of booster doses is still scarce. The aim of our study was to analyze the reported incidence rate (IR), and factors associated with AE, including short-term serious adverse events (SAE) and short-term non-serious adverse events (NSAE), among different vaccine products through the hospital-based Vaccine Adverse Event Reporting System (VAERS). A total of 7432 records were collected during the three-month study pe

APA, Harvard, Vancouver, ISO, and other styles

45

Solforosi, Laura, Lea M. M. Costes, Jeroen T. B. M. Tolboom, et al. "Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques." Nature Communications 14, no. 1 (2023). http://dx.doi.org/10.1038/s41467-023-37715-2.

Full text

Abstract:

AbstractOmicron spike (S) encoding vaccines as boosters, are a potential strategy to improve COVID-19 vaccine efficacy against Omicron. Here, macaques (mostly females) previously immunized with Ad26.COV2.S, are boosted with Ad26.COV2.S, Ad26.COV2.S.529 (encoding Omicron BA.1 S) or a 1:1 combination of both vaccines. All booster vaccinations elicit a rapid antibody titers increase against WA1/2020 and Omicron S. Omicron BA.1 and BA.2 antibody responses are most effectively boosted by vaccines including Ad26.COV2.S.529. Independent of vaccine used, mostly WA1/2020-reactive or WA1/2020-Omicron BA

APA, Harvard, Vancouver, ISO, and other styles

46

Marchese, Anthony M., Matthew Rousculp, John Macbeth, Hadi Beyhaghi, Bruce T. Seet, and Seth Toback. "The Novavax Heterologous COVID Booster Demonstrates Lower Reactogenicity Than mRNA: A Targeted Review." Journal of Infectious Diseases, November 22, 2023. http://dx.doi.org/10.1093/infdis/jiad519.

Full text

Abstract:

Abstract COVID-19 continues to be a global health concern and booster doses are necessary for maintaining vaccine-mediated protection, limiting the spread of SARS-CoV-2. Despite multiple COVID vaccine options, global booster uptake remains low. Reactogenicity, the occurrence of adverse local/systemic side effects, plays a crucial role in vaccine uptake and acceptance, particularly for booster doses. We conducted a targeted review of the reactogenicity of authorized/approved mRNA and protein-based vaccines demonstrated by clinical trials and real-world evidence. It was found that mRNA-based boo

APA, Harvard, Vancouver, ISO, and other styles

47

Wee, Liang En, Jue Tao Lim, Mayank Goel, et al. "Bivalent boosters and risk of post-acute sequelae following vaccine-breakthrough SARS-CoV-2 Omicron infection: a cohort study." Clinical Infectious Diseases, December 5, 2024. https://doi.org/10.1093/cid/ciae598.

Full text

Abstract:

Abstract Background Vaccination has been shown to attenuate the risk of post-acute sequelae following SARS-CoV-2 infection. However, no prior population-based studies have evaluated if updated bivalent boosters reduce risk of post-acute sequelae following Omicron-variant infection, versus ancestral vaccines. Methods National databases were utilised to construct a population-based cohort of adult individuals infected during Omicron-predominant transmission. Risk and excess-burdens (EB) of pre-specified multi-organ new-incident diagnoses at 31-365 days post-SARS-CoV-2 infection were compared bet

APA, Harvard, Vancouver, ISO, and other styles

48

Wee, Liang En, Deanette Pang, Calvin Chiew, et al. "Long-term real-world protection afforded by third mRNA doses against symptomatic SARS-COV-2 infections, COVID-19-related emergency attendances and hospitalizations amongst older Singaporeans during an Omicron XBB wave." Clinical Infectious Diseases, June 6, 2023. http://dx.doi.org/10.1093/cid/ciad345.

Full text

Abstract:

Abstract Background Literature on long-term real-world vaccine effectiveness of SARS-CoV-2 booster vaccines (up to and beyond 360 days) is scarce. We report estimates of protection against symptomatic infection, emergency department (ED) attendances and hospitalizations up to and beyond 360 days post-receipt of booster mRNA vaccines amongst Singaporeans aged ≥60 years during an Omicron XBB wave. Methods We conducted a population-based cohort study including all Singaporeans aged ≥60 years with no documented prior SARS-CoV-2 infection who had previously received ≥3 doses of mRNA vaccines (BNT16

APA, Harvard, Vancouver, ISO, and other styles

49

El Tantawi, Maha, Amira H. Elwan, Reham Hassan, et al. "Assessing vaccinated persons’ intention to take the COVID-19 boosters using a combined theoretical framework: an online survey in Egypt." Scientific Reports 14, no. 1 (2024). http://dx.doi.org/10.1038/s41598-024-72093-9.

Full text

Abstract:

AbstractVaccines, like the Corona Virus Disease-2019 (COVID-19) vaccines, can control diseases, but vaccine hesitancy reduces their use. It is important to assess the intention to use COVID-19 vaccines boosters and the determinants of this intention to help in developing programs to promote the uptake of boosters. An online survey collected data from adults in Egypt between March and June 2022 using a questionnaire that assessed demographic characteristics, and constructs of the Theory of Planned Behaviour (TPB) and the Health Belief Model (HBM). The survey was uploaded to SurveyMonkey and the

APA, Harvard, Vancouver, ISO, and other styles

50

Turabian, Jose Luis. "Comparison of Adverse COVID-19 Vaccines Reactions between First and Second Doses, First Booster and Fourth Doses in General Medicine." International Journal of Research in Virology 1, no. 1 (2024). https://doi.org/10.33425/3065-565x.1002.

Full text

Abstract:

Background: Differential characteristics of the adverse reactions between the different COVID-19 vaccinations shots are not clearly known. Objective: Comparison of adverse reactions that led to consultation with the general practitioner between first and second, third (first booster) and fourth (second booster) doses of COVID-19 vaccines. Methodology: Several longitudinal studies are compared, with the same methodology and population, of adverse COVID-19 vaccines reactions that were the reason for medical consultation, in people with first and second doses from February to July 2021, first boo

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!